Health Condition 1: H521- Myopia
Conditions
Interventions
Intervention1: 0.01% Atropine eye drops: Group A patients will be prescribed atropine eye drops 0.01% along with correction of refractive error for 2 year
Control Intervention1: 0.5% Carboxy methyl ce
Sponsors
Dr Arvind Kumar Morya
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients with age group 05 to 23 years. 2. Gender male and female 3. Best corrected visual acuity should be 6/6 (20/20; LogMAR 0.0) or better in both eyes 4. Spherical equivalent should be equal to or more than -0.25Diopter 5. Both spherical and or cylindrical refraction would be included. Refraction would be based on cycloplegic refraction and subjective acceptance 6. Patients/legal guardian should be willing to use the eye drops on regular compliant basis. 7. Patients/legal guardian should be able to understand and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. History of ocular inflammation or trauma or treatment of refractive error (medical or surgical) 2. Any ocular comorbidity limiting visual assessment, visual improvement. 3. Any type of amblyopia in one or both eyes. 4. Patient lost to follow up within 1 year of the study or not compliant with the treatment advised
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary: To compare the the efficacy and safety of atropine 0.01% eye drops in controlling progression of myopia. Secondary : To evaluate the systemic and ocular side effects of atropine eye drops 0.01% in myopic patients. Timepoint: Change in spherical equivalent at the end of 2 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of atropine 0.01% eye drops in arresting the progression of myopiaTimepoint: To evaluate the efficacy of atropine 0.01% eye drops in arresting the progression of myopia at 2 year of therapy | — |
Countries
India
Contacts
Public ContactDr Arvind Kumar Morya
AIIMS JODHPUR
Outcome results
None listed